Literature DB >> 11802100

Enantioselective analysis of citalopram and metabolites in adolescents.

B Carlsson1, G Olsson, M Reis, J Walinder, C Nordin, J Lundmark, M G Scordo, M L Dahl, F Bengtsson, J Ahlner.   

Abstract

Studies of the antidepressant effect and pharmacokinetics of citalopram have been performed in adults, but the effects on children and adolescents have only been studied to a minor extent despite its increasing use in these age groups. The aim of this study was to investigate a group of adolescents treated for depression, with respect to the steady-state plasma concentrations of the enantiomers of citalopram and its demethylated metabolites desmethylcitalopram and didesmethylcitalopram. Moreover, the authors studied the genotypes for the polymorphic cytochrome P450 enzymes CYP2D6 and CYP2C19 in relation to the different enantiomers. The S/R ratios of citalopram and desmethylcitalopram found in this study of 19 adolescents were similar to studies involving older patients. The concentrations of the R-(-)- and S-(+)-enantiomers of citalopram and desmethylcitalopram were also in agreement with values from earlier studies, the R-(-)-enantiomer (distomer) being the major enantiomer. The results indicate that the use of oral contraceptives may have some influence on the metabolism of citalopram. This might be because of an interaction of the contraceptive hormones with the CYP2C19 enzyme.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11802100     DOI: 10.1097/00007691-200112000-00011

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  9 in total

1.  Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers.

Authors:  Adriana Rocha; Eduardo B Coelho; Stefânia A Sampaio; Vera L Lanchote
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

Review 2.  Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis.

Authors:  Ming Chang; Gunnel Tybring; Marja-Liisa Dahl; Jonatan D Lindh
Journal:  Clin Pharmacokinet       Date:  2014-09       Impact factor: 6.447

3.  Pharmacogenetics to Predict Adverse Events Associated With Antidepressants.

Authors:  Katelyn M Rossow; Ida T Aka; Angela C Maxwell-Horn; Dan M Roden; Sara L Van Driest
Journal:  Pediatrics       Date:  2020-12       Impact factor: 7.124

Review 4.  Clinical applications of CYP genotyping in psychiatry.

Authors:  Edoardo Spina; Jose de Leon
Journal:  J Neural Transm (Vienna)       Date:  2014-09-09       Impact factor: 3.575

5.  Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children.

Authors:  Ida Aka; Christiana J Bernal; Robert Carroll; Angela Maxwell-Horn; Kazeem A Oshikoya; Sara L Van Driest
Journal:  J Pers Med       Date:  2017-11-02

6.  Simultaneous Quantification of Citalopram and its Main Metabolite, 
Desmethylcitalopram, in Human Saliva by UHPLC.

Authors:  Ewelina Dziurkowska; Marek Wesolowski
Journal:  Curr Anal Chem       Date:  2018-12       Impact factor: 1.892

7.  Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders.

Authors:  Stacey L Aldrich; Ethan A Poweleit; Cynthia A Prows; Lisa J Martin; Jeffrey R Strawn; Laura B Ramsey
Journal:  Front Pharmacol       Date:  2019-02-19       Impact factor: 5.810

8.  Pediatric Therapeutic Drug Monitoring for Selective Serotonin Reuptake Inhibitors.

Authors:  Jeffrey R Strawn; Ethan A Poweleit; Chakradhara Rao S Uppugunduri; Laura B Ramsey
Journal:  Front Pharmacol       Date:  2021-10-01       Impact factor: 5.810

Review 9.  Perspectives from the Society for Pediatric Research: pharmacogenetics for pediatricians.

Authors:  Sonya C Tang Girdwood; Katelyn M Rossow; Sara L Van Driest; Laura B Ramsey
Journal:  Pediatr Res       Date:  2021-04-06       Impact factor: 3.756

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.